| Document |
Document Title |
|
WO/2023/215602A1 |
Described herein are methods for producing enriched populations of progenitor rod photoreceptor cells (PRPs) and EVs derived therefrom, as well as methods of using the PRPs and EVs to diagnose and treat retinal disease.
|
|
WO/2023/211226A1 |
Provided is a pharmaceutical composition for preventing or treating hearing loss or tinnitus, the composition comprising mitochondria as an active ingredient. The pharmaceutical composition has the effects of preventing the apoptosis of ...
|
|
WO/2023/208086A1 |
It relates to methods and compositions for determining anatomical response to an VEGF antagonist treatment in a subject's eye, comprising determining a VEGF level in the aqueous humor of the subject or in combination with determining a b...
|
|
WO/2023/211999A1 |
Provided herein are compositions and methods for treating eye disorders. In particular, provided herein are compositions and methods for treating and preventing retinal pigment epithelium (RPE) epithelial-to-mesenchymal transition (EMT),...
|
|
WO/2023/212298A1 |
The present disclosure relates to the treatment and/or prevention of age-related macular degeneration (AMD), including both neovascular AMD ("wet" AMD) and non-neovascular AMD ("dry" AMD), as well as advanced forms of non-neovascular AMD...
|
|
WO/2023/212293A1 |
The present disclosure relates to the treatment and/or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides no...
|
|
WO/2023/210670A1 |
The purpose of the present invention is to remove, prior to administration, particles in a solution preparation filled in a syringe. The present invention provides an injection preparation in which a solution is filled in a syringe, wher...
|
|
WO/2023/212294A1 |
The present disclosure relates to the treatment and/or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and relat...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/206134A1 |
It relates to methods and compositions for determining anatomical response to an VEGF antagonist treatment in a subject's eye, comprising determining a VEGF level in the aqueous humor of the subject, wherein a determined VEGF level highe...
|
|
WO/2023/212417A1 |
The invention provides methods and compositions for use in the treatment and prevention of diseases and conditions of the eye.
|
|
WO/2023/207672A1 |
Use of the RS1 gene in preparing a therapeutic agent for X-linked juvenile retinoschisis is provided. The RS1 gene in an RS1 gene expression cassette is subjected to codon optimization, and the nucleotide sequence of said gene is as show...
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/210657A1 |
The purpose of the present invention is to provide a method for preventing or treating myopia, and a composition used in said method. The present invention provides a method and composition for inhibiting, improving, or treating myopia b...
|
|
WO/2023/209708A1 |
Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more...
|
|
WO/2023/186174A9 |
Provided herein is a gel composition for topical use, which comprises an IL-17 A binding molecule and suitable excipients.
|
|
WO/2023/212719A1 |
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an inherited retinal disease (IRD) (e.g., retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystr...
|
|
WO/2023/205453A1 |
Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.
|
|
WO/2023/204629A1 |
The present invention relates to a method for producing a CFTR activator compound and an intermediate used therefor and, more specifically, to a method for producing a novel compound that enhances the activity of CFTR, and a novel interm...
|
|
WO/2023/205459A1 |
Provided herein are methods of treating a skin affliction, an ophthalmological affliction, or an autoimmune disease comprising administering or applying to an individual having the skin affliction an active agent in a dosage sufficient t...
|
|
WO/2023/204292A1 |
A compound represented by formula (1) [where: A is a heterocyclic ring; R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl; R3 is an alkyl, an alkenyl, or an alkynyl; L is an alkylene or is not present; X1 is ...
|
|
WO/2023/202705A1 |
An ophthalmic preparation and an application thereof in treating presbyopia. The ophthalmic preparation comprises aceclidine and rebamipide, wherein aceclidine and rebamipide jointly have a synergistic effect. Rebamipide can enhance the ...
|
|
WO/2023/204297A1 |
The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, a...
|
|
WO/2023/204291A1 |
The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof that has therapeutic and prophylactic effects on diseases in which orexin type 2 receptors participate, specifically, na...
|
|
WO/2023/204630A1 |
The present invention relates to a composition comprising a cystic fibrosis transmembrane conductance regulator (CFTR) activator as an active ingredient and, more particularly, to a composition having improved solubility, good storage st...
|
|
WO/2023/205788A1 |
Disclosed herein, are hammerhead ribozymes that bind to a target mRNA comprising a NUH ribozyme cleavage site that have enhanced turnover rates. Also described herein, are methods of administering hammerhead ribozymes that bind to a targ...
|
|
WO/2023/205415A1 |
Provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the activation of TFEB and...
|
|
WO/2023/199951A1 |
The present invention addresses the problem of providing a multipotent stem cell imparted with a new function, and a differentiated cell (particularly, an endothelial cell) thereof. The present invention provides a multipotent stem cell ...
|
|
WO/2023/198050A1 |
The present invention relates to the field of biological medicines. Disclosed are a fusion type adeno-associated virus and a use thereof in ear diseases and ophthalmic diseases. The fusion type adeno-associated virus comprises a fusion p...
|
|
WO/2023/198192A1 |
The present invention provides use of a steroid compound in preparing drugs for preventing and/or treating presbyopia. The steroid compound provided by the present invention is represented by formula (I). The steroid compound has the eff...
|
|
WO/2023/201107A1 |
Disclosed herein are colloidally stable heme-albumin complexes, as well as compositions comprising these complexes, methods of making these complexes, and methods of using these complexes. These heme-albumin complexes can comprise from t...
|
|
WO/2023/198737A1 |
The invention relates to an ophthalmological viscoelastic composition comprising an aqueous solution having a viscoelastic base component and having an additive including at least one water-soluble polymer without covalent bonding to the...
|
|
WO/2023/201315A2 |
Provided herein are devices and methods for removing a preservative from a solution, suspension, or emulsion comprising an ophthalmic agent, which substantially maintains one or more activity of the ophthalmic agent after passing through...
|
|
WO/2022/260939A9 |
The present invention relates to agents which inhibit the expression and/or activity of transthyretin (TTR), e.g., a double stranded RNA (dsRNA) agent, or salt thereof, or an antisense oligonucleotide or a gene therapy targeting TTR, and...
|
|
WO/2023/199828A1 |
The present invention provides: a fine particle containing miRNAs that target at least one of a gene associated with the expression of vascular endothelial growth factor (VEGF-A) protein or the leukotriene A4 hydrolase (LTA4H) gene, the ...
|
|
WO/2023/151653A9 |
An oleogel and a preparation method therefor and a use thereof. The oleogel comprises 60-90 wt% of liquid oil, 6-35 wt% of a structuring agent, and 4-15 wt% of water. The liquid oil comprises an unsaturated fatty acid, and the structurin...
|
|
WO/2023/201312A2 |
The present application provides compounds and methods for treating ocular fibrotic pathologies, including using dopamine D2 receptor antagonists for treating proliferative vitreoretinopathy.
|
|
WO/2023/198197A1 |
The present invention provides a free-state PLX5622 crystal form and a preparation method therefor, and in particular, provides crystal forms A, B, C, D, E and F of a compound of formula I which is a free alkali PLX5622 with the chemical...
|
|
WO/2023/169115A9 |
The present invention relates to an adeno-associated virus (AAV) capsid protein having a high affinity with a nervous system, an AAV vector comprising the capsid protein, and an application thereof. The AAV capsid protein has a good affi...
|
|
WO/2023/195543A1 |
The present invention addresses the problem of providing an ophthalmic aqueous composition containing ripasudil and having excellent antiseptic effects. The present invention provides an ophthalmic aqueous composition that contains ripas...
|
|
WO/2023/193694A1 |
The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-...
|
|
WO/2023/196235A1 |
Disclosed herein are methods, devices, and systems for treating lens protein aggregation diseases by reducing the formation of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure. Specifically d...
|
|
WO/2023/193074A1 |
The present invention relates to a pharmaceutical composition comprising the association of desloratadine and a hydrotropic agent, a method for producing same and the uses thereof.
|
|
WO/2023/196835A1 |
Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provid...
|
|
WO/2023/196555A1 |
The present invention includes methods of treating ocular fibrosis of the eye in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of a prolactin-inducible P...
|
|
WO/2023/194797A1 |
Disclosed herein are methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprisi...
|
|
WO/2023/196746A1 |
The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual nucleic acids comprising nucleotide sequences encoding a medium wavelength cone op...
|
|
WO/2023/196842A1 |
Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno- associated virus (AAV) encoding a transgene. Also provi...
|
|
WO/2023/196873A1 |
Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno- associated virus (AAV) encoding a transgene. Also provi...
|
|
WO/2022/251484A9 |
Inappropriate or excessive complement activation is an underlying cause or contributing factor to a number of serious diseases and conditions, and considerable effort has been devoted over the past several decades to exploring various co...
|
